Multivalent HIV vaccine boost compositions and methods of use
Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521Δ11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.
1. A method for inducing an immune response to a human immunodeficiency virus (HIV) comprising administering to a human in need thereof:
i) a prime vaccination comprising an effective amount of a DNA vector encoding Gag-Pol and Env and one or more of Tat, Rev, Nef, Vif, Vpr, or Vpu HIV-1 antigens that, when expressed, are displayed on virus-like particles (VLPs); and
ii) a boost vaccination comprising
a) an effective amount of a first modified vaccinia Ankara (MVA) vector encoding a membrane-bound HIV-1 envelope (Env) protein that, when expressed, is displayed on VLPs, and,
b) an effective amount of a second MVA vector encoding an HIV-1 gp-140 protein.
2. The method of claim 1 , wherein the HIV-1 gpl40 is ADA gpl40.
3. The method of claim 1 , wherein the prime vaccination DNA vector encoding HIV-1 antigens is pGA2/JS7.
4. The method of claim 1 , wherein the boost vaccination is administered 8 weeks after a last prime vaccination.
5. The method of claim 1 , wherein a first prime vaccination is administered at 0 weeks and a second prime vaccination is administered at 8 weeks.
6. The method of claim 1 , wherein the boost vaccination is administered at least 2 times.
7. The method of claim 1 , wherein the boost vaccination is administered at week 16, week 24, and week 40 after administration of a first prime vaccination.
8. A method for boosting an immune response to a human immunodeficiency virus (HIV) comprising administering to a human in need thereof a boost vaccination comprising:
a) an effective amount of a first modified vaccinia Ankara (MVA) vector encoding a membrane-bound HIV-1 envelope (Env) protein that, when expressed, is displayed on virus-like particles (VLPs), and,
b) an effective amount of a second MVA vector encoding an HIV-1 gp-140 protein,
wherein, prior to the administration of the boost vaccination, the human has previously been administered one or more prime vaccinations comprising a DNA vector encoding Gag-Pol and Env and one or more of Tat, Rev, Nef, Vif, Vpr, or Vpu HIV-1 antigens.
9. The method of claim 8 , wherein the first MVA vector is MVA/HIV62B.
10. The method of claim 8 , wherein the HIV-1 gpl40 is ADA gpl40.
11. The method of claim 8 , wherein the boost vaccination is administered 8 weeks after a last prime vaccination.
12. The method of claim 8 , wherein the boost vaccination is administered at least 2 times.
13. The method of claim 8 , wherein the boost vaccination is administered at week 16, week 24, and week 40 after administration of a first prime vaccination.
14. The method of claim 1 , wherein the first MVA vector is MVA/HIV62B.